Dinaciclib Enhances Natural Killer Cell Cytotoxicity Against Acute Myelogenous Leukemia

Overview

Journal Blood Adv

Specialty Hematology

Date 2019 Aug 17

PMID 31416822

Citations 12

Authors

Hyun Don Yun

Dawn K Schirm

Martin Felices

Jeffrey S Miller

Craig E Eckfeldt

Affiliations

Soon will be listed here.

Citing Articles

Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications.

Khattab S, Berisha A, Baran N, Piccaluga P Biomedicines. 2025; 13(1).

PMID: 39857784 PMC: 11760468. DOI: 10.3390/biomedicines13010202.

Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside.

Hassanzadeh A, Shomali N, Kamrani A, Soltani-Zangbar M, Nasiri H, Akbari M EXCLI J. 2024; 23:862-882.

PMID: 38983782 PMC: 11231458. DOI: 10.17179/excli2024-7076.

Harnessing natural killer cell effector function against cancer.

Blunt M, Khakoo S Immunother Adv. 2024; 4(1):ltad031.

PMID: 38223411 PMC: 10787374. DOI: 10.1093/immadv/ltad031.

The role of ARL4C in predicting prognosis and immunotherapy drug susceptibility in pan-cancer analysis.

Zhao H, Yang K, Yue Z, Chen Z, Cheng Z, Sun H Front Pharmacol. 2024; 14:1288492.

PMID: 38178862 PMC: 10765536. DOI: 10.3389/fphar.2023.1288492.

Crosstalk of Mast Cells and Natural Killer Cells with Neurons in Chemotherapy-Induced Peripheral Neuropathy.

Yun H, Goel Y, Gupta K Int J Mol Sci. 2023; 24(16).

PMID: 37628724 PMC: 10454469. DOI: 10.3390/ijms241612543.

References

Miller J, Soignier Y, Panoskaltsis-Mortari A, McNearney S, Yun G, Fautsch S . Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105(8):3051-7. DOI: 10.1182/blood-2004-07-2974. View

Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D . Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010; 9(8):2344-53. DOI: 10.1158/1535-7163.MCT-10-0324. View

Gleason M, Verneris M, Todhunter D, Zhang B, McCullar V, Zhou S . Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012; 11(12):2674-84. PMC: 3519950. DOI: 10.1158/1535-7163.MCT-12-0692. View

Gleason M, Ross J, Warlick E, Lund T, Verneris M, Wiernik A . CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014; 123(19):3016-26. PMC: 4014844. DOI: 10.1182/blood-2013-10-533398. View

Bachanova V, Cooley S, DeFor T, Verneris M, Zhang B, McKenna D . Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014; 123(25):3855-63. PMC: 4064329. DOI: 10.1182/blood-2013-10-532531. View

Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I . Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood. 2014; 124(22):3241-9. PMC: 4239333. DOI: 10.1182/blood-2014-04-569061. View

Vallera D, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl J . IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016; 22(14):3440-50. PMC: 4947440. DOI: 10.1158/1078-0432.CCR-15-2710. View

Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G . Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood. 2016; 127(23):2879-89. PMC: 4900955. DOI: 10.1182/blood-2015-11-680546. View

Romee R, Rosario M, Berrien-Elliott M, Wagner J, Jewell B, Schappe T . Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016; 8(357):357ra123. PMC: 5436500. DOI: 10.1126/scitranslmed.aaf2341. View

10.

Pomeroy E, Lee L, Lee R, Schirm D, Temiz N, Ma J . Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene. 2016; 36(23):3263-3273. PMC: 5464975. DOI: 10.1038/onc.2016.471. View

11.

Sakib Hossain D, Javaid S, Cai M, Zhang C, Sawant A, Hinton M . Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest. 2018; 128(2):644-654. PMC: 5785250. DOI: 10.1172/JCI94586. View

12.

Yun H, Felices M, Vallera D, Hinderlie P, Cooley S, Arock M . Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv. 2018; 2(13):1580-1584. PMC: 6039654. DOI: 10.1182/bloodadvances.2018018176. View